Dergiler / Archives of Rheumatology / 2022 / Cilt: 37 - Sayı: 1

Biological treatment in resistant adult-onset Still’s disease: A single-center, retrospective cohort study

Sayfa
11–18
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The aim of this study was to assess the demographic and clinical characteristics of patients with adult-onset Still’s disease (AOSD) under biological treatment.
📊
Temel Bulgular & Veri:Patients and methods: This retrospective cohort study included a total of 19 AOSD patients (13 males, 6 females; median age: 37 years; range, 28 to 52 years) who received biological drugs due to refractory disease between January 2008 and January 2020.
💡
Sonuç & Katkı:Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved.
🔬Tür:Araştırma Makalesi
📍Kapsam:2008 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: The aim of this study was to assess the demographic and clinical characteristics of patients with adult-onset Still’s disease (AOSD) under biological treatment. Patients and methods: This retrospective cohort study included a total of 19 AOSD patients (13 males, 6 females; median age: 37 years; range, 28 to 52 years) who received biological drugs due to refractory disease between January 2008 and January 2020. The data of the patients were obtained from the patient files. The response to the treatment was evaluated based on clinical and laboratory assessments at third and sixth follow-up visits. Results: Interleukin (IL)-1 inhibitor was prescribed for 13 (68.4%) patients and IL-6 inhibitor prescribed for six (31.6%) patients. Seventeen (89.5%) patients experienced clinical remission. Conclusion: Biological drugs seem to be effective for AOSD patients who are resistant to conventional therapies. Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved.

🔖

Bu Makaleye Atıf Yap

ÇINAR, M., ÇOLAK, S., TEKGÖZ, E., YILMAZ, S., MAMMADOV, M. (2022). Biological treatment in resistant adult-onset Still’s disease: A single-center, retrospective cohort study. Archives of Rheumatology, Cilt: 37 - Sayı: 1, 11–18. https://ajindex.com/articles/447951

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun 2018;93:24-36
  2. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971;30:121-33
  3. Sugiura T, Maeno N, Kawaguchi Y, Takei S, Imanaka H, Kawano Y, et al. A promoter haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population. Arthritis Res Ther 2006;8:R60
  4. Liu Y, Xia C, Chen J, Fan C, He J. Elevated circulating pro-inflammatory low-density granulocytes in adult-onset Still's disease. Rheumatology (Oxford) 2021;60:297-303
  5. Seco T, Cerqueira A, Costa A, Fernandes C, Cotter J. Adult-onset Still's disease: Typical presentation, delayed diagnosis. Cureus 2020;12:e8510
  6. Al-Homood IA. Biologic treatments for adultonset Still’s disease. Rheumatology (Oxford) 2014;53:32-8
  7. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-30
  8. Pay S, Türkçapar N, Kalyoncu M, Simek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 2006;25:639-44
  9. Ruscitti P, Cipriani P, Liakouli V, Guggino G, Carubbi F, Berardicurti O, et al. Managing adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (Baltimore) 2019;98:e15123
  10. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adultonset Still's disease. Autoimmun Rev 2014;13:708-22
  11. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86
  12. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004;31:2189-98
  13. Wada T, Kanegane H, Ohta K, Katoh F, Imamura T, Nakazawa Y, et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine 2014;65:74-8
  14. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol 2013;25:439-48
  15. Hausmann JS. Targeting cytokines to treat autoinflammatory disea